再生障碍性贫血41例临床分析  

Clinical analysis of 41 cases with apiastic anemia

作　　者：黄淑环[1] 蔡成才[1] 伍锦泉[1] 梁卓林[1] 梁月雄[1] 

机构地区：[1]肇庆市第一人民医院,广东肇庆526021

出　　处：《国际医药卫生导报》2006年第1期18-20,共3页International Medicine and Health Guidance News

摘　　要：目的总结41例再生障碍性贫血(再障)患者临床发病特点,诊断及治疗效果。方法对我院10年间确诊的41例再障患者的临床资料进行回顾性分析。结果41例再障患者中慢性再障的治疗有效率为80%,重型再障为42.9%。慢性再障中单用雄激素治疗有效率76.9%,CSA和雄激素联合应用的有效率为83.3%;重型再障中单用雄激素治疗有效率为25%,CSA和雄激素联合应用的有效率为50%。院内死亡5例中,3例死于脑出血。结论雄激素是治疗慢性再障的主要药物,雄激素和CSA联合应用可提高疗效,单用雄激素治疗重型再障效果不佳,目前主张用CSA、ATG治疗,或CSA、ATG、大剂量甲基强的松龙、造血细胞因子联合应用。Objective To analyze the clinical characteristics and diagnosis and treat- ment outcome in 41 cases with aplastic anemia (AA).Method We registered patients newly diagnosed AA between 1993 and 2003 using questionnaires. Retospective analysis was used. Result Of the 41 cases, Treatment effective rate was 80% of chronic AA, 42.9% of severe AA. In chronic AA, the rate was 83.3% in treatment with cyclosporine A combined androgen and 76.9% with androgen alone. In severe AA, the rate was 50% with cyclosporine A co...

关 键 词：再生障碍性贫血 环孢霉素A 雄激素 联合 

分 类 号：R556.5[医药卫生—血液循环系统疾病]